SELB - Selecta Biosciences Inc Stock Price, Fair Value and News

0.84USD-0.01 (-1.18%)Market Closed

Market Summary

USD0.84-0.01

Market Closed

-1.18%

SELB Stock Price

View Fullscreen

SELB RSI Chart

SELB Valuation

Market Cap

136.0M

Price/Earnings (Trailing)

-0.62

Price/Sales (Trailing)

5.23

EV/EBITDA

-0.29

Price/Free Cashflow

-2.65

SELB Price/Sales (Trailing)

SELB Profitability

EBT Margin

-800.91%

Return on Equity

49.91%

Return on Assets

-72.02%

Free Cashflow Yield

-37.76%

SELB Fundamentals

SELB Revenue

Revenue (TTM)

26.0M

Rev. Growth (Yr)

-50.78%

Rev. Growth (Qtr)

26.18%

SELB Earnings

Earnings (TTM)

-219.7M

Earnings Growth (Yr)

-3.1K%

Earnings Growth (Qtr)

-1.9K%

Breaking Down SELB Revenue

Last 7 days

35.5%

Last 30 days

15.1%

Last 90 days

-22.2%

Trailing 12 Months

-31.7%

How does SELB drawdown profile look like?

SELB Financial Health

Current Ratio

1.33

SELB Investor Care

Shares Dilution (1Y)

5.63%

Diluted EPS (TTM)

-1.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	82.7M	48.7M	34.5M	26.0M
2022	108.0M	127.6M	123.9M	110.8M
2021	32.0M	47.3M	67.1M	85.1M
2020	9.7M	12.0M	14.3M	16.6M
2019	1.7M	1.7M	1.6M	7.4M
2018	588.3K	969.5K	1.4M	1.7M
2017	6.1M	4.1M	2.2M	207.0K
2016	7.1M	7.8M	7.3M	8.1M
2015	3.8M	4.5M	5.3M	6.0M
2014	0	0	0	3.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Selecta Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 25, 2023	traber peter g	sold	-747	1.06	-705	chief medical officer
Sep 25, 2023	brunn carsten	sold	-3,107	1.06	-2,932	president and ceo
May 31, 2023	kishimoto takashi kei	gifted	-	-	-53,000	chief scientific officer
May 30, 2023	kishimoto takashi kei	gifted	-	-	-86,000	chief scientific officer
Jan 05, 2023	kishimoto takashi kei	sold	-3,830	1.12919	-3,392	chief scientific officer
Jan 05, 2023	brunn carsten	sold	-15,214	1.12922	-13,473	president and ceo
Jan 05, 2023	traber peter g	sold	-3,912	1.1292	-3,465	chief medical officer
Jan 05, 2023	johnston lloyd p.	sold	-3,830	1.12919	-3,392	chief operations officer
Jan 04, 2023	traber peter g	sold	-9,272	1.13372	-8,179	chief medical officer
Jan 04, 2023	johnston lloyd p.	sold	-7,246	1.13371	-6,392	chief operations officer

Which funds bought or sold SELB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 30, 2024	Avior Wealth Management, LLC	new	-	10.00	10.00	-%
Apr 29, 2024	HAZLETT, BURT & WATSON, INC.	unchanged	-	-	-	-%
Apr 29, 2024	PRINCIPAL FINANCIAL GROUP INC	reduced	-21.33	-2,770	7,957	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-5.07	-24,180	206,259	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	-118	1,950	-%
Apr 23, 2024	HALL LAURIE J TRUSTEE	unchanged	-	-2,000	34,000	0.01%
Apr 23, 2024	AMALGAMATED BANK	reduced	-66.71	-5,000	3,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	sold off	-100	-65,910	-	-%
Apr 19, 2024	Cutler Group LLC / CA	unchanged	-	-	1,000	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	new	-	-	-	-%

Are Funds Buying or Selling SELB?

Are funds buying SELB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SELB

No. of Funds

Unveiling Selecta Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 12, 2024	springer timothy a	36.4%	6,473,184	SC 13D/A
Apr 10, 2024	kalayoglu murat	19.9%	3,538,386	SC 13D/A
Apr 10, 2024	singer michael	4.3%	769,744	SC 13D/A
Mar 28, 2024	springer timothy a	27.9%	194,189,313	SC 13D/A
Mar 11, 2024	fmr llc	-	0	SC 13G/A
Feb 14, 2024	mangrove partners im, llc	2.59%	4,127,258	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Feb 09, 2024	artal international s.c.a.	6.4%	10,455,849	SC 13G/A
Nov 22, 2023	kalayoglu murat	19.9%	39,344,463	SC 13D
Nov 22, 2023	singer michael	13.9%	26,060,927	SC 13D

Recent SEC filings of Selecta Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 22, 2024	8-K	Current Report
Apr 19, 2024	3	Insider Trading
Apr 12, 2024	SC 13D/A	13D - Major Acquisition
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	SC 13D/A	13D - Major Acquisition
Apr 10, 2024	SC 13D/A	13D - Major Acquisition
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	4	Insider Trading

Peers (Alternatives to Selecta Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	5.56%	-15.17%	-9.03	6.22	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.9B	1.8B	-2.25%	-24.69%	-42.88	10.32	76.23%	61.08%
BMRN	15.8B	2.5B	-4.35%	-11.20%	76.99	6.4	13.74%	186.89%
INCY	11.9B	3.8B	-6.50%	-24.30%	15.95	3.16	8.58%	129.81%
MID-CAP
APLS	5.6B	396.6M	-22.91%	-44.64%	-10.5	14	425.83%	18.94%
BBIO	4.8B	-	-9.87%	93.55%	-7.27	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-2.73%	5.06%	-14.83	13.11	440.80%	-27.84%
ARWR	2.9B	240.7M	-18.02%	-34.57%	-9.66	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.68%	-20.30%	-45.81	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-3.49%	-8.60%	25.07	4.5	85.90%	-14.05%
NVAX	652.2M	983.7M	0.22%	-33.81%	-1.2	0.66	-50.36%	17.16%
CRBP	390.9M	881.7K	-1.95%	364.46%	-8.76	466.16	-77.61%	-5.33%
INO	270.2M	4.9M	-11.89%	28.44%	-2	55.51	-54.97%	51.71%
IBIO	6.4M	2.1M	-44.78%	68.18%	-0.24	2.14	-13.45%	66.37%

Selecta Biosciences Inc News

Latest updates

Selecta Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	26.2%	8,266,000	6,551,000	5,249,000	5,938,000	16,795,000	20,710,000	39,273,000	33,999,000	29,937,000	24,427,000	19,663,000	11,050,000	11,951,000	4,646,000	5,315,333	5,984,667	6,654,000	184,000	246,000	277,000	903,000
Operating Expenses	127.4%	44,598,000	19,616,000	23,887,000	24,319,000	25,291,000	22,309,000	25,413,000	23,226,000	25,859,000	26,396,000	19,211,000	18,208,000	19,849,000	18,380,000	16,367,000	18,822,000	19,224,000	11,794,000	16,248,000	11,866,000	15,402,000
S&GA Expenses	235.2%	22,167,000	6,614,000	6,105,000	5,695,000	6,324,000	5,770,000	6,231,000	5,537,000	5,541,000	5,445,000	4,748,000	5,204,000	4,758,000	4,420,000	5,637,000	4,098,000	4,072,000	3,690,000	4,114,000	4,513,000	5,146,000
R&D Expenses	72.5%	22,431,000	13,002,000	17,782,000	18,624,000	18,967,000	16,539,000	19,182,000	17,689,000	20,318,000	20,951,000	14,463,000	13,004,000	15,091,000	13,960,000	10,730,000	14,724,000	15,152,000	8,104,000	12,134,000	7,353,000	10,256,000
EBITDA Margin	-6291.9%	-7.90	0.13	0.24	0.14	0.10	-0.05	-0.05	-0.06	-0.07	-0.97	-1.39	-2.07	-	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	1,273,000	752,000	808,000	807,000	802,000	715,000	707,000	711,000	711,000	711,000	711,000	713,000	365,000	205,000	273,000	1,500,000	388,000	400,000	396,000	1,500,000
Income Taxes	-	-	-	-	-	-288,000	-321,000	-	-	138,000	15,828,000	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-2084.6%	-196,658,000	-9,002,000	-	-	5,605,000	-8,214,000	-	-	12,377,000	-2,066,000	-	-	-	-9,729,000	-	-	-	-	-	-	-
EBT Margin	-36206.4%	-8.01	0.02	0.16	0.09	0.07	-0.08	-0.08	-0.09	-0.11	-1.03	-1.46	-2.16	-	-	-	-	-	-	-	-	-
Net Income	-1873.5%	-177,658,000	-9,002,000	-11,387,000	-21,663,000	5,893,000	-7,893,000	8,601,000	28,778,000	12,239,000	-17,894,000	4,565,000	-24,597,000	-15,446,000	-9,729,000	-24,081,000	-19,620,000	-14,888,000	-11,994,000	-16,394,000	-12,074,000	-14,651,000
Net Income Margin	-706.9%	-8.45	-1.05	-0.72	-0.18	0.32	0.34	0.25	0.26	-0.30	-0.80	-0.96	-2.31	-	-	-	-	-	-	-	-	-
Free Cashflow	-153.4%	-23,350,000	-9,215,000	-9,907,000	-8,895,000	-12,060,000	3,917,000	-12,370,000	-12,319,000	-31,738,000	-10,910,000	-6,661,000	-12,158,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	187.7%	305	106	140	156	166	178	188	146	160	167	181	177	165	181	75.00	89.00	100	40.00	47.00	62.00	44.00
Current Assets	1.0%	91.00	90.00	123	138	148	160	173	130	144	152	167	163	151	167	61.00	74.00	97.00	36.00	44.00	60.00	42.00
Cash Equivalents	-3.4%	77.00	80.00	112	126	106	113	138	113	114	115	126	125	140	146	60.00	73.00	92.00	34.00	30.00	32.00	38.00
Net PPE	-12.7%	2.00	2.00	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00
Goodwill	-	48.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	872.9%	445	46.00	74.00	81.00	72.00	93.00	98.00	90.00	137	186	185	196	183	188	88.00	98.00	91.00	44.00	47.00	48.00	50.00
Current Liabilities	242.1%	68.00	20.00	29.00	27.00	25.00	24.00	34.00	39.00	72.00	96.00	87.00	85.00	82.00	77.00	23.00	30.00	35.00	29.00	32.00	33.00	35.00
Shareholder's Equity	-829.6%	-440	60.00	65.00	75.00	94.00	85.00	90.00	56.00	23.00	-	-	-	-18.01	-	-	-	8.00	-	0.00	15.00	-
Retained Earnings	-40.6%	-614	-436	-427	-416	-394	-400	-392	-401	-430	-442	-424	-429	-404	-389	-379	-355	-335	-320	-308	-335	-280
Additional Paid-In Capital	-64.3%	179	502	498	496	493	490	487	462	457	428	425	414	391	386	371	351	349	320	313	312	280
Shares Outstanding	4.6%	162	155	153	153	153	153	149	124	114	113	114	111	-	-	-	-	-	-	-	-	-
Float	-	-	-	129	-	-	-	150	-	-	-	367	-	-	-	248	-	-	-	59.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-152.7%	-23,286	-9,215	-9,895	-8,765	-11,849	4,353	-12,271	-11,864	-31,460	-10,746	-6,043	-12,133	-7,250	65,637	-11,808	-11,698	-12,876	-11,122	-7,197	-20,240	-12,748
Share Based Compensation	509.4%	14,144	2,321	3,783	2,276	2,276	2,601	3,564	2,753	2,253	1,904	1,783	1,780	1,236	1,296	1,481	1,409	1,427	1,303	1,251	1,180	2,483
Cashflow From Investing	-	6,497	-	-12.00	28,124	5,489	-29,937	-99.00	9,545	9,722	-1,802	-2,615	-22,445	-166	-286	-154	-135	-9.00	11,512	4,845	-16,119	-374
Cashflow From Financing	156.8%	14,081	-24,789	-2,586	149	-	612	36,875	1,728	21,156	1,450	8,984	21,307	-190	20,948	-957	-5,370	68,534	5,028	372	31,107	80.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SELB Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Comprehensive Income [Abstract]
Collaboration and license revenue	$ 26,004	$ 110,777	$ 85,077
Operating expenses:
Research and development	71,839	72,377	68,736
General and administrative	40,581	23,862	20,938
Total operating expenses	112,420	96,239	89,674
Operating (loss) income	(86,416)	14,538	(4,597)
Investment income	4,964	2,073	44
Foreign currency transaction gain (loss), net	38	(22)	0
Interest expense	(2,833)	(3,031)	(2,844)
Change in fair value of warrant liabilities	12,746	20,882	(2,339)
Change in fair value of contingent value right liability	(18,300)	0	0
Change in fair value of forward contract liabilities	(149,600)	0	0
Other income, net	691	330	15
(Loss) income before income taxes	(238,710)	34,770	(9,721)
Income tax benefit (expense)	19,000	609	(15,966)
Net (loss) income	(219,710)	35,379	(25,687)
Other comprehensive (loss) income:
Foreign currency translation adjustment	(53)	18	(2)
Unrealized gain (loss) on marketable securities	11	(10)	(1)
Total comprehensive (loss) income	$ (219,752)	$ 35,387	$ (25,690)
Net (loss) income per share:
Basic (in dollars per share)	$ (1.66)	$ 0.24	$ (0.22)
Diluted (in dollars per share)	$ (1.66)	$ 0.10	$ (0.22)
Weighted-average common shares outstanding:
Basic (in shares)	155,109,561	144,758,555	114,328,798
Diluted (in shares)	155,109,561	145,874,889	114,328,798

SELB Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 76,911	$ 106,438
Marketable securities	0	28,164
Accounts receivable	5,870	6,596
Unbilled receivables	2,981	3,162
Prepaid expenses and other current assets	4,967	3,778
Total current assets	90,729	148,138
Non-current assets:
Property and equipment, net	2,113	2,794
Right-of-use asset, net	10,068	11,617
In-process research and development assets	150,600	0
Goodwill	48,163	0
Long-term restricted cash	1,377	1,311
Investments	2,000	2,000
Other assets	0	26
Total assets	305,050	165,886
Current liabilities:
Accounts payable	3,150	316
Accrued expenses and other current liabilities	15,572	14,084
Loan payable	0	8,476
Lease liability	2,166	1,608
Deferred revenue	2,311	593
Warrant liabilities	720	0
Contingent value right liability	15,983	0
Forward contract liabilities	28,307	0
Total current liabilities	68,209	25,077
Non-current liabilities:
Loan payable, net of current portion	0	17,786
Lease liability, net of current portion	8,789	10,055
Deferred revenue, net of current portion	3,538	0
Warrant liabilities, net of current portion	5,674	19,140
Contingent value right liability, net of current portion	342,617	0
Deferred tax liabilities, net	15,853	0
Total liabilities	444,680	72,058
Commitments and contingencies (Note 19)
Series A Preferred Stock, $0.0001 par value; 548,375 and no shares authorized as of December 31, 2023 and December 31, 2022, respectively; 435,120.513 and no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	296,851	0
Options for Series A Preferred Stock	3,703	0
Stockholders’ (deficit) equity:
Preferred stock, $0.0001 par value; 9,451,625 and 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; no shares issued and outstanding as of December 31, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value; 350,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 161,927,821 and 153,042,435 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	16	15
Additional paid-in capital	179,047	493,308
Accumulated deficit	(614,647)	(394,937)
Accumulated other comprehensive loss	(4,600)	(4,558)
Total stockholders’ (deficit) equity	(440,184)	93,828
Total liabilities, convertible preferred stock, and stockholders’ (deficit) equity	$ 305,050	$ 165,886

About Selecta Biosciences Inc

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Carsten Brunn Ph.D.
WEBSITE	https://selectabio.com
INDUSTRY	Biotechnology
EMPLOYEES	64

Selecta Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Selecta Biosciences Inc? What does SELB stand for in stocks?

SELB is the stock ticker symbol of Selecta Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Selecta Biosciences Inc (SELB)?

As of Thu Feb 29 2024, market cap of Selecta Biosciences Inc is 136.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SELB stock?

You can check SELB's fair value in chart for subscribers.

What is the fair value of SELB stock?

You can check SELB's fair value in chart for subscribers. The fair value of Selecta Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Selecta Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SELB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Selecta Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether SELB is over valued or under valued. Whether Selecta Biosciences Inc is cheap or expensive depends on the assumptions which impact Selecta Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SELB.

What is Selecta Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 29 2024, SELB's PE ratio (Price to Earnings) is -0.62 and Price to Sales (PS) ratio is 5.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SELB PE ratio will change depending on the future growth rate expectations of investors.